Universal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 113,992 Structure Therapeutics Inc. (NASDAQ:GPCR)

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 113,992 shares of the company's stock, valued at approximately $3,091,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.20% of Structure Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Deep Track Capital LP lifted its holdings in shares of Structure Therapeutics by 129.4% during the 4th quarter. Deep Track Capital LP now owns 2,800,000 shares of the company's stock worth $75,936,000 after acquiring an additional 1,579,492 shares during the period. Vestal Point Capital LP lifted its holdings in shares of Structure Therapeutics by 50.0% during the 4th quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company's stock worth $46,782,000 after acquiring an additional 575,000 shares during the period. Boxer Capital Management LLC bought a new stake in shares of Structure Therapeutics during the 4th quarter worth approximately $13,560,000. Marshall Wace LLP lifted its stake in Structure Therapeutics by 339.6% in the 4th quarter. Marshall Wace LLP now owns 583,207 shares of the company's stock valued at $15,817,000 after purchasing an additional 450,531 shares during the last quarter. Finally, Foresite Capital Management VI LLC bought a new position in Structure Therapeutics in the 4th quarter valued at approximately $11,390,000. Institutional investors and hedge funds own 91.78% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. William Blair assumed coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They set an "outperform" rating for the company. HC Wainwright dropped their price target on shares of Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating for the company in a research note on Monday, May 12th. Finally, Citigroup assumed coverage on shares of Structure Therapeutics in a research note on Friday, May 2nd. They set a "buy" rating and a $60.00 price target for the company. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $79.86.

Structure Therapeutics Price Performance

Shares of GPCR traded down $0.34 during trading hours on Friday, hitting $21.13. 1,227,836 shares of the stock were exchanged, compared to its average volume of 866,683. Structure Therapeutics Inc. has a fifty-two week low of $13.22 and a fifty-two week high of $55.66. The business has a 50-day moving average of $22.00 and a 200-day moving average of $25.06. The firm has a market capitalization of $1.21 billion, a P/E ratio of -28.55 and a beta of -1.87.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). As a group, analysts forecast that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.